Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors

Podobné jednotky

• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  Autor: Shang-Gin Wu, a další
  Vydáno: (2017-07-01)
• The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
  Autor: Wu, Shang-Gin, a další
  Vydáno: (2016)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  Autor: Wu, Shang-Gin, a další
  Vydáno: (2016)
• IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
  Autor: Wu, Shang-Gin, a další
  Vydáno: (2019)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  Autor: Gow, Chien-Hung, a další
  Vydáno: (2005)